Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, filed this Form 6-K on January 7, 2026. The filing serves to incorporate by reference a press release dated January 7, 2026 (Exhibit 99.1) into the company's active registration statements on Form F-3 and Form S-8.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to update registration statements with a press release and does not contain a standalone financial statement or quarterly results table.
Material Changes
No material changes to financial results or operations are detailed within the text of this specific Form 6-K. The document references the press release for the substantive announcement but does not summarize the content of that release.
Guidance, Outlook, and Risks
The filing reiterates that the company's business faces significant risks and that forward-looking statements are subject to uncertainties. It directs investors to the Annual Report on Form 20-F for the year ended December 31, 2024, filed on May 15, 2025, for a comprehensive list of risk factors. The company notes that actual results could materially differ from anticipated outcomes.
Key Facts for Investor Verification
- Review the attached press release (Exhibit 99.1) for the specific announcement triggering this filing.
- Consult the Annual Report on Form 20-F (filed May 15, 2025) for detailed risk factors and historical financial data.
- Verify the impact of the January 7, 2026 announcement on the company's active registration statements (Form F-3 No. 333-291644 and Form S-8 Nos. 333-255124 and 333-272515).